1364. Efficacy of Omadacycline Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials

BACKGROUND: Omadacycline (OMC) is a once-daily agent with IV and oral formulations. One Phase 3 trial for community-acquired bacterial pneumonia (CABP; OPTIC) and two Phase 3 trials for acute bacterial skin and skin structure infections (ABSSSI; OASIS-1 and OASIS-2) were completed. OMC and comparato...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendes, Rodrigo E, Castanheira, Mariana, Armstrong, Eliana S, Steenbergen, Judith N, Flamm, Robert K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252834/
http://dx.doi.org/10.1093/ofid/ofy210.1195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252834/
http://dx.doi.org/10.1093/ofid/ofy210.1195

Ejemplares similares